High-Definition Transcranial Direct Current Stimulation as a Treatment of Negative Symptoms of Schizophrenia

A Research on High-Definition Transcranial Direct Current Stimulation as a Treatment of Negative Symptoms in Patients With Schizophrenia

In this study, investigators designed a double-blind randomized trial to prove a more reliable evidence to show how the treatment by using high-definition transcranial direct current stimulation (HD-tDCS) can relieve negative symptoms in patients with predominant negative symptoms of schizophrenia, especially on improving participants' anhedonia condition and social cognition, through stimulating the left dorsolateral prefrontal cortex (DLPFC). Participants will be divided into active and sham HD-tDCS groups equally.

Study Overview

• Status: Terminated
• Conditions: Schizophrenia
• Intervention / Treatment: Device: HD-tDCS; Device: Sham HD-tDCS

Detailed Description

Schizophrenia is one of the most disabling psychiatric disorders that almost 1% worldwide population suffer from this devastating illness. The clinical expression of this illness has been categorized into different dimensions, though most of the patients are well treated with antipsychotic medication, the negative symptom is still one of the very refractory symptoms. Emerging evidence shows that transcranial direct current stimulation (tDCS) is a promising treatment for schizophrenia negative symptoms, however, findings are still controversial. HD-tDCS can provide a more stable and accurate direct current comparing with traditional tDCS, which gives a hope to treat negative symptoms in a more reliable way.

An association between negative symptoms and grey matter reductions in the prefrontal cortex is found, moreover, even during rest, hypoactivity of the prefrontal cortex, particularly of the left dorsolateral, and of the anterior cingulate regions, has been linked to negative symptoms of schizophrenia. It has been observed that tDCS could relatively alleviate negative symptoms in patients with schizophrenia by stimulating the left DLPFC through an anodal electrode, which has been proved can also modulate brain functional connectivity and have clinical improvements.

Half of the participants with a clinical presentation of predominant negative symptoms will be stimulated by active HD-tDCS and the rest will have a sham stimulation. HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at 1 (T2) and 3 (T3) months. A Soterix Medical 4x1 HD-tDCS will be used with the anode placed over the left DLPFC (F3), surrounded by four cathodal electrodes at F5, F1, FC3 and AF3, based on the 10/20 international EEG system. All the outcomes will be assessed at baseline (T0, before HD-tDCS sessions), one day after the 10th HD-tDCS sessions (T1), and also at T2 and T3. Both participants and investigators will be blind to this treatment.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200030
      • Shanghai Mental Health Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• patients with diagnostic schizophrenia by DSM-IV
• patients at an age between 18-60 years of Han nationality
• 1) baseline score equal or higher than 4 in at least two items in negative symptoms at PANSS; 2) or baseline score equal or higher than 3 points in at least 1/3 items (including apathy) for negative symptoms; and 3)No more than 2 items have a score higher than 3 points for positive symptoms at PANSS.
• willing to participate in the experiment and take treatment

Exclusion Criteria:

• other psychiatric diagnoses
• criteria for bipolar disorder; dementia; other psychotic disturbs; substance-related disorders
• schizophrenia caused by organic diseases
• other mental disorders caused by drugs and alcohol
• IQ<70
• presence of serious suicidal behaviour
• claustrophobic or pregnancy
• metal implantation in vivo
• specific tDCS limitations (such as anatomic problems and high sensitivity on current)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: HD-tDCS group; This HD-tDCS group will be stimulated by active HD-tDCS.	Device: HD-tDCS; HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
SHAM_COMPARATOR: Sham HD-tDCS group; This sham HD-tDCS group will have a sham stimulation with HD-tDCS.	Device: Sham HD-tDCS; HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Positive and Negative Syndrome Scale (PANSS)	a 30-items, 7-point rating scale; the 7 rating points represent increasing levels of psychopathology: 1= absent, 2= minimal, 3= mild, 4 = moderate, 5= moderate-severe, 6= severe, 7= extreme; of the 16 items, 7 were chosen to constitute Positive Scale, 7 items for Negative Scale and the remaining 16 items for a General Psychopathology Scale.	Change from baseline through study completion and sustained effects at 1 and 3 months.
The Scale for the Assessment of Negative Symptoms (SANS)	a 24-items, 5-point rating scale; the 5 rating points represent increasing levels of psychopathology: 0= absent, 1= mild, 2= moderate, 3= severe, 4= extreme; of the 24 items, the first 6 items for Affective Flattening, 5 items for Alogia, 5 items for Avolition, 5 items for Anhedonia, and the remaining 3 items for Attention.	Change from baseline through study completion and sustained effects at 1 and 3 months.
The Clinical Assessment Interview for Negative Symptoms (CAINS)	including CAINS and CAINS self-reported checklist	Change from baseline through study completion and sustained effects at 1 and 3 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the Temporal Experience of Pleasure Scale (TEPS)	a self-reported questionnaire	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Emotional Expression Scale (EES)	a self-reported questionnaire	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Belief About Pleasure Scales (BAPS)	a self-reported questionnaire	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Emotional Regulation Questionnaire (ERQ)	a self-reported questionnaire	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Beck Depression Inventory (BDI)	a self-reported questionnaire	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Effort Expenditure for Rewards Task (EEfRT)	a computer test	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Belief Updating Task	a computer test	Change from baseline through study completion and sustained effects at 1 and 3 months.
the Anticipatory and Consummatory Pleasure (ACP) task performances	a computer test	Change from baseline through study completion and sustained effects at 1 and 3 months.

Collaborators and Investigators

• Sponsor: Shanghai Mental Health Center
• Collaborators: Chinese Academy of Sciences

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 16, 2018
• Primary Completion (ACTUAL): September 26, 2020
• Study Completion (ACTUAL): September 26, 2020

Study Registration Dates

• First Submitted: June 27, 2018
• First Submitted That Met QC Criteria: July 18, 2018
• First Posted (ACTUAL): July 27, 2018

Study Record Updates

• Last Update Posted (ACTUAL): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 18, 2021
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Keywords: schizophrenia; negative symptoms; HD-tDCS
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: 17411970000

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No